Prosecution Insights
Last updated: November 04, 2026

Exo-Biomed

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Exo-Biomed currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a single distinct examiner, CASEY SHEA HAGOPIAN, and is located in 1 distinct art unit. The prosecution for this portfolio is currently limited to this active proceeding.

The fact that there is a lone pending matter indicates a very narrow window of active prosecution at this time. CASEY SHEA HAGOPIAN is the only individual currently reviewing the company's work. Furthermore, the activity is restricted to a single art unit, which simplifies the procedural landscape for the company's legal representatives.

With the current workload and the sole examiner, the company's immediate success in the Biotechnology & Pharmaceuticals area depends on this specific interaction. The busiest examiner manages all of the company's current workload at the patent office. This focus allows for a deep analysis of the individual's past behavior and the specific division's trends.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HAGOPIAN, CASEY SHEA 1 54.2% +33.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18982079 PHYSIOLOGICALLY AND MECHANICALLY BIOCOMPATIBLE ARTIFICIAL PANCREAS AND PHYSICALLY CROSSLINKED POLYVINYL ALCOHOL HYDROGELS AND SOLIDS FROM WHICH THE BIOARTIFICIAL PANCREAS IS MANUFACTURED HAGOPIAN, CASEY SHEA —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18982079 PHYSIOLOGICALLY AND MECHANICALLY BIOCOMPATIBLE ARTIFICIAL PANCREAS AND PHYSICALLY CROSSLINKED POLYVINYL ALCOHOL HYDROGELS AND SOLIDS FROM WHICH THE BIOARTIFICIAL PANCREAS IS MANUFACTURED HAGOPIAN, CASEY SHEA —

Top Art Units

Art UnitApps
1617 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18982079 PHYSIOLOGICALLY AND MECHANICALLY BIOCOMPATIBLE ARTIFICIAL PANCREAS AND PHYSICALLY CROSSLINKED POLYVINYL ALCOHOL HYDROGELS AND SOLIDS FROM WHICH THE BIOARTIFICIAL PANCREAS IS MANUFACTURED HAGOPIAN, CASEY SHEA 1617 §103§112 Non-Final OA — Pending Dec 16, 2024

Managing Exo-Biomed's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Exo-Biomed have?

Exo-Biomed has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Exo-Biomed applications?

Casey Shea Hagopian has the most, with 1 of Exo-Biomed's pending office actions.

What technology area are Exo-Biomed's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month